Virginia G. Kaklamani, MD, DSc

Virginia Kaklamani, MD, DSc, is a professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio, as well as the leader of the breast cancer program at the Mays Cancer Center, home to the UT Health San Antonio MD Anderson Cancer Center

Articles

Typical Approaches for Treatment Selection in the Third Line and Beyond

August 10th 2023

Experts share their go-to regimens in the third-line and higher setting of HER2+ metastatic breast cancer, and touch on the factors that support their decision-making.

HER2+ mBC: Emerging Agents in the Third-Line and Higher Setting

August 3rd 2023

Debu Tripathy, MD, discusses novel therapies being developed for later-line treatment of HER2+ mBC.

T-DXd: Updated Results from the DESTINY-Breast Studies and Practical Considerations for Followup

August 3rd 2023

Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.

Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB

July 27th 2023

Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.

Ongoing Second-Line Trials in Patients with HER2+ mBC and Expert Clinical Perspective

July 27th 2023

Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.

Use of ADCs in the Second-Line Treatment of HER2+ mBC

July 20th 2023

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC

July 20th 2023

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

Breast Cancer Management: Future Directions in Fertility Preservation

July 19th 2023

Closing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.

Timing Fertility Preservation in Patients With Breast Cancer Undergoing Surgery

July 19th 2023

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.

Data Updates and Ongoing Trials in the HER2+ Adjuvant Space

July 13th 2023

Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.

Identifying Patients Suitable for Adjuvant Neratinib

July 13th 2023

Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.

Treatment Guidelines on Fertility Preservation in Breast Cancer

July 12th 2023

Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.

Monitoring Patients With Breast Cancer Receiving OFS

July 12th 2023

A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .

Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen

July 6th 2023

Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.

How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?

July 6th 2023

Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.

Factors Informing the Selection and Use of OFS in Breast Cancer

July 5th 2023

Expert perspectives on the appropriate selection and use of OFS in premenopausal patients with breast cancer.

Data From the SOFT and TEXT Trials: Combination Therapy With OFS in Breast Cancer

July 5th 2023

Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the SOFT and TEXT clinical trials to elucidate combination treatment strategies with ovarian function suppression (OFS).

Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities

June 29th 2023

Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.

HER2+ Early Breast Cancer: Treatment Optimization and Review of Standard-of-Care Neoadjuvant Regimens

June 29th 2023

Heather McArthur, MD, and Debu Tripathy, MD, lead a discussion on risk stratification and optimizing treatment for HER2+ early breast cancer (eBC), followed by a review of standard-of-care systemic therapy regimens in the preoperative/neoadjuvant setting.

Fertility Preservation in Breast Cancer: Use of GnRH Agonists

June 28th 2023

Comprehensive insight to available gonadotropin-releasing hormone (GnRH) agonists in breast cancer and the role they play when thinking about fertility preservation.